A Phase Ib/II Clinical Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma

Trial Profile

A Phase Ib/II Clinical Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs Amcasertib (Primary) ; Napabucasin (Primary) ; Sorafenib
  • Indications Liver cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Boston Biomedical
  • Most Recent Events

    • 11 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
    • 06 Jun 2017 Results (n=20) from phase I part of the trial, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 03 Jun 2017 Interim results (n=27) presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, according to a Boston Biomedical media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top